John A. Robertson, MD; Isidro B. Salusky, MD; William G. Goodman, MD; Keith C. Norris, MD; Jack W. Coburn, MD
Aluminum absorption from aluminum-containing phosphate-binding antacids is a major source of aluminum loading in patients on dialysis (1). The aluminum is retained when renal function is impaired, and it has been implicated in the pathogenesis of osteomalacia and encephalopathy in these patients (2). Sucralfate, the basic aluminum salt of sucrose sulfate, contains 21% aluminum by weight (3); it is widely used to treat peptic ulcer disease and gastritis (4). Sucralfate does not alter plasma aluminum levels in normal subjects (5). Aluminum can dissociate, however, from sucralfate at a low pH (6) and become bioavailable. Our case report and study data
Robertson JA, Salusky IB, Goodman WG, Norris KC, Coburn JW. Sucralfate, Intestinal Aluminum Absorption, and Aluminum Toxicity in a Patient on Dialysis. Ann Intern Med. ;111:179–181. doi: 10.7326/0003-4819-111-2-179
Download citation file:
Published: Ann Intern Med. 1989;111(2):179-181.
Emergency Medicine, Gastroenterology/Hepatology, Nephrology, Renal Replacement Therapy.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use